INDIANAPOLIS--(BUSINESS WIRE)--Semafore Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics targeting the phosphoinositide-3-kinase (PI3K) pathway for the treatment of cancer and other serious diseases, announced today that its board of directors has named Michael D. Becker as the company’s acting chief executive officer.
